誉衡药业
(002437)
| 流通市值：71.91亿 | | | 总市值：76.26亿 |
| 流通股本：21.03亿 | | | 总股本：22.30亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,007,061,544.15 | 539,105,711.33 | 2,135,451,494.88 | 1,664,997,338.49 |
| 营业收入 | 1,007,061,544.15 | 539,105,711.33 | 2,135,451,494.88 | 1,664,997,338.49 |
| 二、营业总成本 | 854,148,219.96 | 463,882,978.06 | 1,906,201,168.54 | 1,463,760,914.56 |
| 营业成本 | 540,198,440.93 | 293,392,928.78 | 1,167,082,041.34 | 892,117,691.73 |
| 税金及附加 | 16,292,790.32 | 8,234,491.95 | 32,945,250.04 | 25,187,399.78 |
| 销售费用 | 214,597,356.59 | 127,223,530.82 | 496,289,795.89 | 411,395,500.83 |
| 管理费用 | 47,704,736.15 | 22,688,402.02 | 131,797,389.7 | 85,874,163 |
| 研发费用 | 33,712,944.22 | 11,570,107.05 | 78,427,205.91 | 49,714,579.12 |
| 财务费用 | 1,641,951.75 | 773,517.44 | -340,514.34 | -528,419.9 |
| 其中:利息费用 | 1,916,298.09 | 916,345.81 | 2,480,335.32 | 1,795,775.39 |
| 其中:利息收入 | 2,769,569.46 | 1,387,168.03 | 5,095,443.46 | 3,723,490.24 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 4,255,315.28 | 17,633,869.7 | 5,977,821.1 | 37,690,053.1 |
| 加:投资收益 | 855,955.72 | 435,988.1 | 136,525,191.03 | -565,419.78 |
| 资产处置收益 | 12,520,228.38 | 11,157,869.1 | 3,542,703.45 | 3,672,501.28 |
| 资产减值损失(新) | -424,965.27 | -405,377.25 | -10,279,426.44 | -930,377.77 |
| 信用减值损失(新) | -55,426.55 | -34,974.87 | 26,330.79 | 16,215.64 |
| 其他收益 | 13,464,198.75 | 3,258,797.56 | 39,868,070.65 | 24,134,568.42 |
| 四、营业利润 | 183,528,630.5 | 107,268,905.61 | 404,911,016.92 | 265,253,964.82 |
| 加:营业外收入 | 244,652.92 | 7,980.66 | 6,330,581.64 | 4,996,334.88 |
| 减:营业外支出 | 386,562.26 | 146,925.43 | 1,624,660.95 | 916,973.7 |
| 五、利润总额 | 183,386,721.16 | 107,129,960.84 | 409,616,937.61 | 269,333,326 |
| 减:所得税费用 | 21,053,210.89 | 10,462,749.51 | 27,259,809.86 | 21,409,752.07 |
| 六、净利润 | 162,333,510.27 | 96,667,211.33 | 382,357,127.75 | 247,923,573.93 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 162,333,510.27 | 96,667,211.33 | 382,357,127.75 | 247,923,573.93 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 158,985,005.58 | 94,926,073.47 | 376,905,170.2 | 243,763,036.93 |
| 少数股东损益 | 3,348,504.69 | 1,741,137.86 | 5,451,957.55 | 4,160,537 |
| 扣除非经常损益后的净利润 | 130,377,585.84 | 62,942,231.17 | 199,145,728.83 | 178,162,705.84 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.07 | 0.04 | 0.17 | 0.11 |
| (二)稀释每股收益 | 0.07 | 0.04 | 0.17 | 0.11 |
| 八、其他综合收益 | -2,275,845.63 | -1,530,963.76 | -1,098,908.06 | -639,692.29 |
| 归属于母公司股东的其他综合收益 | -2,275,845.63 | -1,530,963.76 | -1,098,908.06 | -639,692.29 |
| 九、综合收益总额 | 160,057,664.64 | 95,136,247.57 | 381,258,219.69 | 247,283,881.64 |
| 归属于母公司股东的综合收益总额 | 156,709,159.95 | 93,395,109.71 | 375,806,262.14 | 243,123,344.64 |
| 归属于少数股东的综合收益总额 | 3,348,504.69 | 1,741,137.86 | 5,451,957.55 | 4,160,537 |
| 公告日期 | 2026-08-27 | 2026-04-28 | 2026-04-28 | 2025-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |